Year: 2020
Type: review
Abstract: BACKGROUND: Hepatic steatosis is a common chronic liver disease that can progress into more severe stages of NAFLD or promote the development of life-threatening secondary diseases for some of those affected. These include the liver itself (nonalcoholic steatohepatitis or NASH; fibrosis and cirrhosis, and hepatocellular carcinoma) or other organs such as the vessels and the heart (cardiovascular disease) or the islets of Langerhans (type 2 diabetes). In addition to elevated caloric intake and a sedentary lifestyle, genetic and epigenetic predisposition contribute to the development of NAFLD and the secondary diseases. SCOPE OF REVIEW: We present data from genome-wide association studies (GWAS) and functional studies in rodents which describe polymorphisms identified in genes relevant for the disease as well as changes caused by altered DNA methylation and gene regulation via specific miRNAs. The review also provides information on the current status of the use of genetic and epigenetic factors as risk markers. MAJOR CONCLUSION: With our overview we provide an insight into the genetic and epigenetic landscape of NAFLD and argue about the applicability of currently defined risk scores for risk stratification and conclude that further efforts are needed to make the scores more usable and meaningful.
Source: Molecular Metabolism
Authors: Wenke Jonas, Annette Schürmann
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, hepatic steatosis, genetic susceptibility, epigenetic factors, DNA methylation, microRNA, genome-wide association study, genetic polymorphism, nonalcoholic steatohepatitis, liver fibrosis, hepatocellular carcinoma, cardiovascular disease, type 2 diabetes, risk score, risk stratification
Open Access status: gold
Estimated APC paid: $2,700
Award: G3354324101
OpenAlex ID: W3095035989
